269 related articles for article (PubMed ID: 17914575)
1. Loss of TP53-DNA interaction induced by p.C135R in lung cancer.
Aranda M; Gonzalez-Nilo F; Riadi G; Díaz V; Perez J; Martel G; Hainaut P; Mimbacas A
Oncol Rep; 2007 Nov; 18(5):1213-7. PubMed ID: 17914575
[TBL] [Abstract][Full Text] [Related]
2. Mutational analysis of p51A/TAp63gamma, a p53 homolog, in non-small cell lung cancer and breast cancer.
Sunahara M; Shishikura T; Takahashi M; Todo S; Yamamoto N; Kimura H; Kato S; Ishioka C; Ikawa S; Ikawa Y; Nakagawara A
Oncogene; 1999 Jun; 18(25):3761-5. PubMed ID: 10391684
[TBL] [Abstract][Full Text] [Related]
3. Reduced transcription of the RB2/p130 gene in human lung cancer.
Xue Jun H; Gemma A; Hosoya Y; Matsuda K; Nara M; Hosomi Y; Okano T; Kurimoto F; Seike M; Takenaka K; Yoshimura A; Toyota M; Kudoh S
Mol Carcinog; 2003 Nov; 38(3):124-9. PubMed ID: 14587097
[TBL] [Abstract][Full Text] [Related]
4. p53 gene alteration in atypical epithelial lesions and carcinoma in patients with idiopathic pulmonary fibrosis.
Kawasaki H; Ogura T; Yokose T; Nagai K; Nishiwaki Y; Esumi H
Hum Pathol; 2001 Oct; 32(10):1043-9. PubMed ID: 11679937
[TBL] [Abstract][Full Text] [Related]
5. Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer.
Okano T; Gemma A; Hosoya Y; Hosomi Y; Nara M; Kokubo Y; Yoshimura A; Shibuya M; Nagashima M; Harris CC; Kudoh S
Oncol Rep; 2006 Mar; 15(3):545-9. PubMed ID: 16465410
[TBL] [Abstract][Full Text] [Related]
6. TP53 mutation, allelism and survival in non-small cell lung cancer.
Nelson HH; Wilkojmen M; Marsit CJ; Kelsey KT
Carcinogenesis; 2005 Oct; 26(10):1770-3. PubMed ID: 15905205
[TBL] [Abstract][Full Text] [Related]
7. Relationship between TP53 tumour suppressor gene mutations and smoking-related bulky DNA adducts in a lung cancer study population from Hungary.
Anna L; Holmila R; Kovács K; Gyorffy E; Gyori Z; Segesdi J; Minárovits J; Soltész I; Kostic S; Csekeo A; Husgafvel-Pursiainen K; Schoket B
Mutagenesis; 2009 Nov; 24(6):475-80. PubMed ID: 19643813
[TBL] [Abstract][Full Text] [Related]
8. p53: an overview of over two decades of study.
Cheah PL; Looi LM
Malays J Pathol; 2001 Jun; 23(1):9-16. PubMed ID: 16329542
[TBL] [Abstract][Full Text] [Related]
9. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism.
Szymanowska A; Jassem E; Dziadziuszko R; Borg A; Limon J; Kobierska-Gulida G; Rzyman W; Jassem J
Lung Cancer; 2006 Apr; 52(1):9-14. PubMed ID: 16499995
[TBL] [Abstract][Full Text] [Related]
10. Alterations of Fas (APO-1/CD 95) gene and its relationship with p53 in non small cell lung cancer.
Boldrini L; Faviana P; Pistolesi F; Gisfredi S; Di Quirico D; Lucchi M; Mussi A; Angeletti CA; Baldinotti F; Fogli A; Simi P; Basolo F; Fontanini G
Oncogene; 2001 Oct; 20(45):6632-7. PubMed ID: 11641789
[TBL] [Abstract][Full Text] [Related]
11. Elevated risk of squamous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms.
Popanda O; Edler L; Waas P; Schattenberg T; Butkiewicz D; Muley T; Dienemann H; Risch A; Bartsch H; Schmezer P
Lung Cancer; 2007 Jan; 55(1):25-34. PubMed ID: 17059853
[TBL] [Abstract][Full Text] [Related]
12. [TP53 mutations and molecular epidemiology].
Otsuka K; Ishioka C
Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
[TBL] [Abstract][Full Text] [Related]
13. [p53 alterations and chromosome 17 aberrations in non-small cell lung cancer].
Tsuji T; Tagawa Y; Hisamatsu T; Nakamura S; Terada R; Sawai T; Yasutake T; Ayabe H
Gan To Kagaku Ryoho; 1997 Jul; 24 Suppl 2():263-8. PubMed ID: 9263513
[TBL] [Abstract][Full Text] [Related]
14. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.
Petitjean A; Mathe E; Kato S; Ishioka C; Tavtigian SV; Hainaut P; Olivier M
Hum Mutat; 2007 Jun; 28(6):622-9. PubMed ID: 17311302
[TBL] [Abstract][Full Text] [Related]
15. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
Wu JY; Wang J; Lai JC; Cheng YW; Yeh KT; Wu TC; Chen CY; Lee H
Ann Surg Oncol; 2008 Nov; 15(11):3272-7. PubMed ID: 18712569
[TBL] [Abstract][Full Text] [Related]
16. KLF6: mutational analysis and effect on cancer cell proliferation.
Yin D; Komatsu N; Miller CW; Chumakov AM; Marschesky A; McKenna R; Black KL; Koeffler HP
Int J Oncol; 2007 Jan; 30(1):65-72. PubMed ID: 17143513
[TBL] [Abstract][Full Text] [Related]
17. A nonsense mutation (Arg-196-Term) in exon 6 of the human TP53 gene identified in small cell lung carcinoma.
Hayes VM; Oosthuizen CJ; Kotze MJ; Marx MP; Buys CH
Mol Cell Probes; 1996 Oct; 10(5):393-5. PubMed ID: 8910896
[TBL] [Abstract][Full Text] [Related]
18. Analysis of TP53 gene mutations in human lung cancer: comparison of capillary electrophoresis single strand conformation polymorphism assay with denaturing gradient gel electrophoresis and direct sequencing.
Holmila R; Husgafvel-Pursiainen K
Cancer Detect Prev; 2006; 30(1):1-6. PubMed ID: 16458448
[TBL] [Abstract][Full Text] [Related]
19. [Interaction of p53 with p53 response element like binding sequence at upstream of hepatitis B virus enhancer I].
Qu JH; Zhu MH; Lin J; Ni CR; Li FM; Zhu Z; Yu GZ
Ai Zheng; 2004 May; 23(5):502-7. PubMed ID: 15142443
[TBL] [Abstract][Full Text] [Related]
20. Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study.
Fouquet C; Antoine M; Tisserand P; Favis R; Wislez M; Commo F; Rabbe N; Carette MF; Milleron B; Barany F; Cadranel J; Zalcman G; Soussi T
Clin Cancer Res; 2004 May; 10(10):3479-89. PubMed ID: 15161705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
